Glycoprotein Ibα polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients

Diabetes

Volumn 56, Issue 5, 2007, Pages 1429-1435

  Corsetti, James P ^a,c   Ryan, Dan ^a   Moss, Arthur J ^a   Rainwater, David L ^b   Zareba, Wojciech ^a   Sparks, Charles E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOSE; GLYCOPROTEIN IB ALPHA; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; NITRATE; PHOSPHOLIPASE A2; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; LIPOPROTEIN; PHOSPHOLIPASE A; THROMBIN RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; CLAUDICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRESSLER SYNDROME; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; RECURRENCE RISK; THROMBOCYTE FUNCTION; AMINO ACID SUBSTITUTION; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DIABETIC ANGIOPATHY; GENETICS; GENOTYPE; HEART INFARCTION; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REPRODUCIBILITY; RISK FACTOR;

AMINO ACID SUBSTITUTION; BIOLOGICAL MARKERS; CHOLESTEROL; DIABETIC ANGIOPATHIES; FEMALE; GENOTYPE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; MALE; MYOCARDIAL INFARCTION; PHOSPHOLIPASES A; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 34248209094     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1573     Document Type: Article

References (46)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:101-112, 2001
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
3. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937-942, 1999
4. American Diabetes Association: Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12:573-579, 1989
5. Varughese GI, Tomson J, Lip GYH: Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract 59:798-816, 2005
6. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
7. Kunicki TJ: The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 22:14-20, 2002
8. Meisel C, Lopez JA, Stangl K: Role of platelet glycoprotein polymorphisms in cardiovascular diseases. Naunyn-Schmiedebergs Arch Pharmacol 369:38-54, 2004
9. Ware J: Molecular analyses of the platelet glycoprotein Ib-IX-V receptor. Thromb Haemost 79:466-464, 1998
10. Zareba W, Pancio G, Moss AJ, Kalaria VG, Marder VJ, Weiss HJ, Watelet LFM, Sparks CE: Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. Thromb Haemost 86:791-799, 2001
11. Yee DL, Bray PF: Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Semin Thromb Hemost 30:591- 600, 2004
12. 2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 252:1331-1338, 2006
13. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM, Arora R, Marcus FI, Watelet LFM, Case RB: Thrombogenic factors and recurrent coronary events. Circulation 99:2517-2522, 1999
14. Corsetti JP, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rainwater DL, Sparks CE: Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. Atherosclerosis 171:351-358, 2003
15. Rainwater DL, Moore PH, Shelledy WR, Dyer TD: Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res 38:1261-1266, 1997
16. Rainwater DL: Electrophoretic separation of LDL and HDL subclasses. Methods Mol Biol 110:137-151, 1998
17. Corsetti JP, Zareba W, Moss AJ, Sparks CE: Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis 183:293-300, 2005
18. Hato T, Minamoto Y, Fukuyama T, Fujita S: Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol 80:1222-1224, 1997
19. Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S, Maurer G, Mayr WR, Panzer S: Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 90:117-123, 1998
20. Ito T, Ishida F, Shimodaira S, Kitano K: Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int J Hematol 70:47-51, 1999
21. Ardissino D, Mannucci PA, Merlini F, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M: Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 94:46-51, 1999
22. Ishida F, Ito t, Takei M, Shimodaira S, Kitano K, Kiyosawa K: Genetic linkage of Kozad sequence polymorphism of the platelet glycoprotein Ibα with human platelet antigen-2 and variable number of tandem repeats polymorphism, and its relationship with coronary artery disease. Br J Haematol 111:1247-1249, 2000
23. Ozelo MC, Origa AF, Aranha FJP, Mansur AP, Annichino-Bizzacchi JM, Costa FF, Pollak ES, Arruda VR: Platelet glycoprotein Ibα polymorphisms modulate the risk for myocardial infarction. Thromb Haemost 92:384-386, 2004
24. Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y: Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 96:3281-3286, 1997
25. Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V: Polymorphisms of platelet membrane glycoprotein Ibα associated with arterial thrombotic disease. Blood 92:2771-2776, 1998
26. Mikkelsson J, Perola M, Penttila A, Karhunen PJ: Platelet glycoprotein Ib HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 104:876-880, 2001
27. Faraday N, Martinez EA, Scharpf RB, Kasch-Semenza L, Dorman T, Pronovost PJ, Perler B, Gerstenblith G, Bray PF: Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. Anesthesiology 101:1291-1297, 2004
28. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C: Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 28:1392-1395, 1997
29. Sonoda A, Murata M, Ito D, Tanahashi N, Ohta A, Tada Y, Takeshita E, Yoshida T, Saito I, Yamamoto M, Ikeda Y, Fukuuchi Y, Watanabe K: Association between platelet glycoprotein Ibα genotype and ischemic cerebrovascular disease. Stroke 31:493-497, 2000
30. Sonoda A, Murate M, Ikeda Y, Fukuuchi Y, Watanabe K: Stroke and platelet glycoprotein Ibα polymorphism. Thromb Haemost 85:573-574, 2001
31. 145 dimorphism in platelet glycoprotein Ibα in an Italian population. Transfusion 36:891-894, 1996
32. Li CQ, Garner SF, Davies J, Smethurst PA, Wardell MR, Ouwehand WH: Theonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbα express HPA-2 epitopes and show equal binding of von Willebrand factor. Blood 95:205-211, 2000
33. Jilma-Stohlawetz P, Homoncik M, Jilma B, Knechtelsdorfer M, Unger P, Mannhalter C, Santoso S, Panzer S: Glycoprotein Ib polymorphism influence platelet plug formation under high shear rates. Br J Haematol 120:652-655, 2003
34. Boncler MA, Golanski J, Paczuski R, Watala C: Polymorphisms of glycoprotein Ib affect the inhibition oby aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation. J Mol Med 80:796-801, 2002
35. Yee DL, Wood J, Bergeron A, Sun C, Dong JF, Bray PF: Thr-145 and VNTR C/D polymorphisms on glycoprotein Ib demonstrate increased platelet reactivity to shear stress and ristocetin (Abstract). Blood 102:783a, 2003
36. Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, Vauterin S, Kroll H, Santoso S, Deckmyn H: Von Willebrand factor but not α-thrombin binding to platelet glycoprotein Ibα is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vasc Biol 23:1302-1307, 2003
37. Porto I, Leone AM, Nanni L, Sciahbasi A, De Vita M, Lanza GA, Andreotti F: Interplay of platelet polymorphisms, risk factors, and von Willebrand factor, and flow-mediated conditions in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease. Blood Coagul Fibrinolysis 16:97-104, 2005
38. Matsubara Y, Murata M, Hayashi T, Suzuki K, Okamura Y, Handa M, Ishihara H, Shibano T, Ikeda Y: Platelet glycoprotein Ib alpha polymorphisms affect the interaction with von Willebrand factor under flow conditions. Br J Haematol 128:533-539, 2005
39. de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA: Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes. Arterioscler Thromb Vasc Biol 26:1086-1093, 2006
40. Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496-1504, 2004
41. 2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 90:3100-3105, 2005
42. 2 in atherosclerosis. Arterioscler Thromb Vasc Biol 25:923-931, 2005
43. 2: a new kid on the block. Clin Chem 52:1645-1650, 2006
44. 2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 14:347-352, 2003
45. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 3:57-68, 2002
46. 2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51:2264-2273, 2005